RC
NKTR icon

Rangeley Capital’s Nektar Therapeutics NKTR Stock Holding History

Rangeley Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$489K Buy
+7,000
New +$512K 0.45% 59
2025
Q4 		– Sell
-4,895
Closed -$279K – 150
2025
Q3 		$279K Buy
+4,895
New +$162K 0.24% 74

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rangeley Capital's NKTR Position: Q2 2026 in Review

Rangeley Capital opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 7,000 shares worth $489K. The stake represents 0.45% of the portfolio and ranks #59 among its holdings. This is a return to the name: Rangeley Capital previously reported a position in NKTR as recently as Q3 2025.

Rangeley Capital first reported a position in NKTR in Q3 2025 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Rangeley Capital held 7,000 shares of Nektar Therapeutics worth $489K as of Q2 2026.
  • Nektar Therapeutics was a new Rangeley Capital position in Q2 2026.
  • Nektar Therapeutics made up 0.45% of Rangeley Capital's portfolio in Q2 2026, its #59 holding.
  • Rangeley Capital first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.